Journal article
Phase II trial of bevacizumab (A), lenalidomide (R), docetaxel (D), and prednisone (P) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).
Authors
Huang X; Ning YM; Mulquin M; Madan RA; Gulley JL; Kluetz PG; Adelberg D; Arlen PM; Parnes HL; Adesunloye B
Journal
Journal of Clinical Oncology, Vol. 29, No. 15_suppl, pp. 4574–4574
Publisher
American Society of Clinical Oncology (ASCO)
Publication Date
May 20, 2011
DOI
10.1200/jco.2011.29.15_suppl.4574
ISSN
0732-183X